Differences in time to patient access to innovative cancer medicines in six European countries.
Europe
access
early access programs
off-label use
oncology
reimbursement
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
20 Oct 2023
20 Oct 2023
Historique:
revised:
01
09
2023
received:
14
07
2023
accepted:
19
09
2023
medline:
21
10
2023
pubmed:
21
10
2023
entrez:
21
10
2023
Statut:
aheadofprint
Résumé
Patients across Europe face inequity regarding access to anticancer medicines. While access is typically evaluated through reimbursement status or sales data, patients can receive first access through early access programs (EAPs) or off-label use. This study aims to assess the time to patient access at the hospital level, considering different indications and countries. (Pre-)registered access to six innovative medicines (Olaparib, Niraparib, Ipilimumab, Osimeritinib, Nivolumab and Ibritunib) was measured using a cross-sectional survey. First patient access to medicines and indications were collected using the hospital databases. Nineteen hospitals from Hungary, Italy, the Netherlands, Belgium, Switzerland and France participated. Analysis showed that some hospitals achieved patient access before national reimbursement, primarily through EAPs. The average time from EMA-approval to patient access for these medicines was 2.1 years (Range: -0.9-7.1 years). Hospitals in Italy and France had faster access compared to Hungary and Belgium. Variation was also found within countries, with specialized hospitals (x̄: -0.9 years; SD: 2.0) more likely to provide patient access prior to national reimbursement than general hospitals (x̄: 0.4 years; SD: 2.9). Contextual differences were observed, with EAPs or off-label use being more prevalent in Switzerland than Hungary. Recent EMA-approved indications and drug combinations reached patients at a later stage. Substantial variation in patient access time was observed between and within countries. Improving pricing and reimbursement timelines, fostering collaboration between national health authorities and market authorization holders, and implementing nationally harmonized, data-generating EAPs can enhance timely and equitable patient access to innovative cancer treatments in Europe.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Fair Pricing Network
Informations de copyright
© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
IQVIA. Global oncology trends 2017: advances, complexity and cost. 2017.
Pignatti F, Wilking U, Postmus D, Wilking N, Delgado J, Bergh J. The value of anticancer drugs: a regulatory view. Nat Rev Clin Oncol. 2022;19(3):207-215. doi:10.1038/s41571-021-00584-z
IQVIA. EFPIA Patients W.A.I.T.: Indicator 2021 Survey. 2022.
Organization WH. Constitution of the World Health Organization. Bull World Health Organ 2002;80(12):983-984.
Uyl-de Groot CA, Heine R, Krol M, Verweij J. Unequal access to newly registered cancer drugs leads to potential loss of life-years in Europe. Cancers (Basel). 2020;12(8):e2313 doi:10.3390/cancers12082313
Cherny N, Sullivan R, Torode J, Saar M, Eniu A. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol. 2016;27(8):1423-1443. doi:10.1093/annonc/mdw213
European Medicines Agency. The European regulatory system for medicines: A consistent approach to medicines regulation across the European Union. 2016.
Reddy NK, Subbiah V. Right to try, expanded access use, project facilitate, and clinical trial reform. Ann Oncol. 2021;32(9):1083-1086. doi:10.1016/j.annonc.2021.06.016
Cherny NI, Sullivan R, Torode J, Saar M, Eniu A. ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe. Ann Oncol. 2017;28(11):2633-2647. doi:10.1093/annonc/mdx521
Vokinger KN, Muehlematter UJ. Accessibility of cancer drugs in Switzerland: time from approval to pricing decision between 2009 and 2018. Health Policy. 2020;124(3):261-267. doi:10.1016/j.healthpol.2019.12.006
Detiček A, Locatelli I, Kos M. Patient access to medicines for rare diseases in European countries. Value Health. 2018;21(5):553-560. doi:10.1016/j.jval.2018.01.007
Ferrario A. Time to entry for new cancer medicines: from European Union-wide marketing authorization to patient access in Belgium, Estonia, Scotland, and Sweden. Value Health. 2018;21(7):809-821. doi:10.1016/j.jval.2018.01.003
Kandolf Sekulovic L, Guo J, Agarwala S, et al. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. Eur J Cancer. 2018;104:201-209. doi:10.1016/j.ejca.2018.09.013
Salmasi V, Lii TR, Humphreys K, Reddy V, Mackey SC. A literature review of the impact of exclusion criteria on generalizability of clinical trial findings to patients with chronic pain. Pain Rep. 2022;7(6):e1050. doi:10.1097/pr9.0000000000001050
Patil S. Early access programs: benefits, challenges, and key considerations for successful implementation. Perspect Clin Res. 2016;7(1):4-8. doi:10.4103/2229-3485.173779
Herbrand AK, Schmitt AM, Briel M, et al. Association of supporting trial evidence and reimbursement for off-label use of cancer drugs. JAMA Netw Open. 2021;4(3):e210380. doi:10.1001/jamanetworkopen.2021.0380
Compassionate use. 2022.
Rémuzat C, Urbinati D, Mzoughi O, el Hammi E, Belgaied W, Toumi M. Overview of external reference pricing systems in Europe. J Mark Access Health Policy. 2015;3.1:e27675. doi:10.3402/jmahp.v3.27675
Kawalec P, Tesar T, Vostalova L, et al. Pharmaceutical regulation in central and eastern European countries: a current review. Front Pharmacol. 2017;8:892. doi:10.3389/fphar.2017.00892
Stargardt T, Schreyögg J. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation. Appl Health Econ Health Policy. 2006;5(4):235-247. doi:10.2165/00148365-200605040-00005
Büssgen M, Stargardt T. Changes in launch delay and availability of pharmaceuticals in 30 European markets over the past two decades. BMC Health Serv Res. 2022;22(1):1457. doi:10.1186/s12913-022-08866-7
Martinalbo J, Bowen D, Camarero J, et al. Early market access of cancer drugs in the EU. Ann Oncol. 2016;27(1):96-105. doi:10.1093/annonc/mdv506
Vreman RA, Strigkos G, Leufkens HGM, Schünemann HJ, Mantel-Teeuwisse AK, Goettsch WG. Addressing uncertainty in relative effectiveness assessments by HTA organizations. Int J Technol Assess Health Care. 2022;38(1):e17. doi:10.1017/s026646232100177x
Nicod E, Kanavos P. Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions. Health Policy. 2012;108(2):167-177. doi:10.1016/j.healthpol.2012.09.012
Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106(1):36-39. doi:10.1002/cpt.1426
Schwarzer R, Rochau U, Saverno K, et al. Systematic overview of cost-effectiveness thresholds in ten countries across four continents. J Comp Eff Res. 2015;4(5):485-504. doi:10.2217/cer.15.38
Pham FY, Jacquet E, Taleb A, et al. Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019. Int J Cancer. 2022;151(8):1345-1354. doi:10.1002/ijc.34129
Gann CN, Morsli N, Kaiser R. Industry corner: perspectives and controversies: the challenges of patient access to new medicines. Ann Oncol. 2017;28(3):658-663. doi:10.1093/annonc/mdw569
European Commission. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems. 1998 https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:31989L0105
Lawlor R, Wilsdon T, Darquennes E, et al. Accelerating patient access to oncology medicines with multiple indications in Europe. J Mark Access Health Policy. 2021;9(1):1964791. doi:10.1080/20016689.2021.1964791
De Medicijnsluis: Hoe nu verder? 2023.
Dutch Ministry of Health WaS. Keeping medicines affordable. https://www.government.nl/topics/medicines/keeping-medicines-affordable
Interpharma. Pharma-Markt Schweiz. 2019 https://www.interpharma.ch/wp-content/uploads/2020/01/ly_iph.01.19.002_-_pharmamarkt_schweiz_2019_d_web-komprimiert.pdf
Pignatti F, Gravanis I, Herold R, Vamvakas S, Jonsson B, Marty M. The European medicines agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation. Clin Cancer Res. 2011;17(16):5220-5225. doi:10.1158/1078-0432.Ccr-11-0623
Carlo De Pietro PC, Isabelle Sturny LC, Edwards-Garavoglia S, Anne Spranger FW, Quentin W. Switzerland Health system review. 2015 https://apps.who.int/iris/bitstream/handle/10665/330252/HiT-17-4-2015-eng.pdf?sequence=5&isAllowed=y
Gori S, di Maio M, Pinto C, et al. Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM). Tumori. 2011;97(4):442-448. doi:10.1177/030089161109700405
Prada M, Ruggeri M, Sansone C, De Fazio D, Tettamanti A, Mantovani M. Timeline of authorization and reimbursement for oncology drugs in Italy in the last 3 years. Medicine Access @ Point of Care. 2017;1:maapoc.0000007. doi:10.5301/maapoc.0000007
Zhong L, Tran AT, Tomasino T, Nugent E, Smith JA. Cost-effectiveness of niraparib and Olaparib as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer. J Manag Care Spec Pharm. 2018;24(12):1219-1228. doi:10.18553/jmcp.2018.24.12.1219
Vintura. Improving time to patient access to innovative oncology therapies in Europe: every day counts. 2020.
Wang Z, Norris SL, Bero L. The advantages and limitations of guideline adaptation frameworks. Implement Sci. 2018;13(1):72. doi:10.1186/s13012-018-0763-4
Syed ST, Gerber BS, Sharp LK. Traveling towards disease: transportation barriers to health care access. J Community Health. 2013;38(5):976-993. doi:10.1007/s10900-013-9681-1
Jacquet E, Kerouani-Lafaye G, Grude F, et al. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years. Eur J Cancer. 2021;149:82-90. doi:10.1016/j.ejca.2021.03.008
Balasubramanian G, Morampudi S, Chhabra P, Gowda A, Zomorodi B. An overview of compassionate use programs in the European Union member states. Intractable Rare Dis Res. 2016;5(4):244-254. doi:10.5582/irdr.2016.01054
Bayle A, Hollebecque A, Pistilli B, Massard C, Marabelle A. Re: comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years: French temporary authorisation for use (ATU) and early access to therapeutic innovations: there are still many patients slipping through the cracks. Eur J Cancer. 2021;156:217-221. doi:10.1016/j.ejca.2021.06.044
Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017;359:j4530. doi:10.1136/bmj.j4530
Oncologie M. Dostarlimab bij recidief of gevorderd mismatch repair-deficiënt endometriumcarcinoom. 2023.